Abbott Labs’s most recent trend suggests a bearish bias. One trading opportunity on Abbott Labs is a Bear Call Spread using a strike $127.00 short call and a strike $132.00 long call offers a potential 23.76% return on risk over the next 20 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $127.00 by expiration. The full premium credit of $0.96 would be kept by the premium seller. The risk of $4.04 would be incurred if the stock rose above the $132.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Abbott Labs is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Abbott Labs is bearish.
The RSI indicator is at 35 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Abbott Hosts Conference Call for Third-Quarter Earnings
Thu, 23 Sep 2021 13:00:00 +0000
Abbott (NYSE: ABT) will announce its third-quarter 2021 financial results on Wednesday, Oct. 20, 2021, before the market opens.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
Wed, 22 Sep 2021 21:50:09 +0000
Abbott (ABT) closed at $124.65 in the latest trading session, marking a -0.38% move from the prior day.
U.S. government to buy point-of-care COVID-19 tests from Abbott, Celltrion -source
Tue, 21 Sep 2021 21:10:08 +0000
The U.S. government has agreed to purchase point-of care COVID-19 tests from Abbott Laboratories and Celltrion Inc to ship to nursing homes and other high risk populations as part of its broader plan to purchase $2 billion in rapid coronavirus tests, a person familiar with the matter said on Tuesday. The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the person said.
Abbott’s (ABT) Portico With FlexNav System Gets FDA Approval
Tue, 21 Sep 2021 14:55:02 +0000
Abbott’s (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Elon Musk chips in $50 million for SpaceX Inspiration4’s children’s cancer fundraising effort
Mon, 20 Sep 2021 14:54:00 +0000
Billionaire Jared Isaacman, who paid for the SpaceX Inspiration4 flight, pledged $100 million St. Jude Children’s Research Hospital and set a goal of raising an additional $100 million by February 2022.
Follow Us on Facebook